Skip to main content

Table 3  Sensitivity analysis

From: Efficacy of quetiapine for delirium prevention in hospitalized older medical patients: a randomized double-blind controlled trial

 

Placebo (n = 57)

Quetiapine (n = 57)

OR (95% CI)

Interaction Effect, P-value

Age group

<  75 years (n = 54)

n = 28

n = 26

 

.481 for delirium incidence

1.0 for 30-day mortality

0.057 for 90-day mortality

Delirium incidence, n (%)

3 (10.7)

3 (11.5)

1.09 (0.20–5.94)

Mortality, n (%)

   

 30 days

2 (7.1)

1 (3.8)

0.52 (0.04–6.10)

 90 days

7 (25.0)

2 (7.7)

0.25 (0.05–1.34)

≥ 75 years (n = 60)

n = 29

n = 31

 

Delirium incidence, n (%)

2 (6.9)

5 (16.1)

2.60 (0.46–14.59)

Mortality, n (%)

   

 30 days

0 (0.0)

0 (0.0)

0.00

 90 days

2 (6.9)

5 (16.1)

2.60 (0.46–14.59)

Length of hospital stay

≤ 5 days (n = 61)

n = 35

n = 26

 

.938 for delirium incidence

.998 30-day mortality

.088 for 90-day mortality

Delirium incidence, n (%)

2 (5.7)

2 (7.7)

1.38 (0.18–10.46)

Mortality, n (%)

   

 30 days

1 (1.6)

0 (0.0)

0.00

 90 days

3 (8.6)

4 (15.4)

1.94 (0.40–9.53)

>  5 days (n = 53)

n = 22

n = 31

 

Delirium incidence, n (%)

3 (13.6)

6 (19.4)

1.52 (0.34–6.87)

Mortality, n (%)

   

 30 days

1 (4.5)

1 (3.2)

0.70 (0.04–11.83)

 90 days

6 (27.3)

3 (9.7)

0.29 (0.06–1.30)

  1. n number, OR Odds ratios, CI Confidence Interval, P P-value